Introduction
Although molecular genetic analysis provides preand Alzheimer's disease. However, immediate therapy is not the only goal of predictive testing. dictive medicine with a potentially very powerful and versatile tool, predictive evaluation is not There are many reasons why at-risk individuals opt for testing for a disease for which no cure currently dependent solely upon modern molecular techniques. High blood pressure, obesity, serum cholesexists. Prominent among these include being able to readjust lives to the unavoidable prospect of a terol levels, family history, behavioural traits and many other features have long been recognized as shortened period of health and/or to be able to plan social and reproductive lives. The hope of risk factors and hence predictors of future disease in otherwise apparently healthy individuals. However, being found not to have the disease in question features prominently for many, but counsellees the application of recombinant DNA methodology has greatly increased the power and scope of predictoften find themselves trapped in a complex mesh of psychological and social pressures to undergo ive (and preventive) medicine.
In the absence of possibilities for therapeutic predictive testing. Well-informed pre-test counselling is an essential component of the testing process, intervention, such advances in predictive tests can be expected to generate all kinds of ethical but it must be recognized that for many adult genetic conditions, particularly those which are problems in their wake. Indeed, for an increasing number of adult-onset disorders, recently developed currently incurable, some people consciously choose not to be tested so as to preserve uncertainly predictive tests confer little or no direct therapeutic benefit upon the patient, e.g. Huntington's disease and so the possibility of hope.
and males, although the absence of a normal allele
Inheritance: models and mechanisms in the hemizygous state often results in males being more severely affected than females.
Patterns of inheritance
To understand the spectrum of human genetic dis-
Variable penetrance and expressivity
ease, it is first necessary to consider the way in which genes may be inherited. Most inherited disFor some diseases, all individuals who carry the orders follow a simple Mendelian form of transmisdefective gene manifest a clinical phenotype. In such sion through families, that is the inheritance patterns cases, penetrance of the disorder is said to be obey Mendel's two laws of inheritance. First, genes complete. However, the inheritance of certain gene are units that segregate; members of the same pair mutations does not invariably give rise to a disease of genes, alleles, are never present in the same phenotype. Diseases in which the inherited disease gamete. Second, genes assort independently; memallele is not invariably expressed as a clinical phenobers of different pairs of genes move to gametes type are said to exhibit partial or incomplete penetrindependently of each other. Almost all human genes
ance. This represents a potentially important source are located within 23 pairs of chromosomes, 22 of of error in the ascertainment of whether or not an which are called autosomes. The other pair are the individual is actually a carrier of the defect in sex chromosomes; females have two X chromosomes question. An allied concept is that of variable whereas males have an X and a Y chromosome.
expressivity which is used to describe the variation Inheritance patterns are determined by whether a in pathological symptoms in those individuals in gene is located on an autosome or a sex chromosome whom the presence of the gene is evident from its and whether or not a mutant allele is able to affect clinical effects. Variable penetrance and expressivity the phenotype in the presence of a normal or result from a subtle interplay of both genetic and wild-type allele. In addition, a few diseases follow a environmental influences which can together be cytoplasmic mode of inheritance that is independent termed the genotype-phenotype relationship (discusof the inheritance of chromosomes. Mitochondria, sed below). almost all of which are inherited maternally in the cytoplasm of the ovum, have their own genome and Genomic imprinting and its relevance to a limited number of human genetic diseases result from inherited abnormalities of mitochondrial DNA.
disease
Monk2 loosely defined genomic imprinting as the 'differential modification of the maternal and paternal
Dominance and recessiveness
contributions to the zygote, resulting in the differential expression of parental alleles during development A disorder is considered dominant if clinical symptoms appear in the heterozygote in whom only one and in the adult'. This differential modification appears to be essential for normal development, allele is defective. In such cases, the disease allele is said to be dominant over the wild-type allele.
since parthenogenetic embryos (whether diploid paternal or diploid maternal) do not survive to term: Dominant mutations often result in a clinical phenotype by giving rise to reduced or abnormal expression in diploid maternal embryos, fetal development is normal but development of the extra-embryonic of a gene product. This gene product is often a receptor or a structural, carrier or regulatory protein membranes is abnormal. In diploid paternal embryos, it is the other way around (reviewed in Monk).2 rather than an enzyme (reviewed in Wilkie1). For the clinical phenotype to become apparent in a recessive Clearly, maternal and paternal chromosomes must differ epigenetically, and in such a way that different disorder, both alleles must be mutant (homozygous state). A disease allele may be said to be recessive developmental programmes are followed. In principle, imprinting must be established either to the wild-type allele in cases where production of 50% of the normal level of the gene product in the before, or early in, gametogenesis, must be stable enough to be retained in somatic cells, and must be heterozygote is sufficient to avoid clinical symptoms. This gene product is often an enzyme but may also capable of being erased in the germline at every generation prior to the fresh establishment of the be a regulatory molecule (e.g. tumour suppressor protein; see below). In the case of an X-linked imprinting pattern. The idea that imprinting might involve DNA methylation was proposed by Monk recessive disease, affected males who carry the disease lesion are said to be hemizygous since they et al. 3 on the grounds that this post-synthetic modification was heritable, reversible and known to play do not carry a wild-type homologous X chromosome which serves to mask clinical expression of the a role in the control of gene expression. This view soon received solid support from the results of studies disorder in females. By contrast, in X-linked dominant disorders, the mutation is evident in both females on transgenic mice.4,5 The regulation of the process of imprinting both spatially and temporally is, how-(e.g. skewed X inactivation found in manifesting carriers of Duchenne muscular dystrophy). By conever, not yet fully understood (reviewed in Razin and Cedar6; Efstratiadis7; Barlow8).
trast, X inactivation may be protective, as in cases where multiple X chromosomes are present (e.g. XXY, Genomic imprinting appears to contribute to the occurrence of insulin-dependent diabetes mellitus XXX) and all but one are inactivated. DNA methylation may be involved in this process, and so X (IDDM). In HLA-DR4-positive diabetics, there is evidence of the existence of a gene or genes affecting inactivation may be regarded as a special case of genomic imprinting. HLA-DR4 IDDM susceptibility positioned in the region of 11p15 where the genes for insulin (INS) and insulin-like growth factor II (IGF2) are located. IDDM-associated alleles for polymorphisms in this Introduction also evident in some tumours, including Wilms'
The diagnostic setting in medical genetics is basically tumour and hereditary non-chromaffin paragangliof two distinct kinds: (i) confirmation/exclusion of a omas. The predisposition to paragangliomas, also particular disease in symptomatic patients and (ii) referred to as glomus tumours or chemodectomas, prediction in asymptomatic people. In the first, a is inherited as an autosomal dominant trait.
disease may already be suspected in an individual Interestingly, all familial patients appear to have through clinical observation, and a DNA test may inherited the trait from their father, whereas offspring then help to confirm or exclude the diagnosis of the from obligate female carriers do not develop tumours.
disease in question. Ultimate confirmation will howLinkage studies support the existence of genetic ever only be obtained once the pathological lesion heterogeneity in the predisposition to these tumours, in the affected gene has been detected in the patient. with two genes being located in different regions of If this is not possible, indirect methods of genotype chromosome 11q.10,11 On the basis of these observaanalysis (see below) can provide a very powerful tions, an interesting model for tumour initiation and diagnostic tool either on their own or in combination progression has been proposed by Mariman et al.11 with independent phenotypic investigations. The As patients often develop more than one tumour greater the clinical heterogeneity manifested by a affecting different glomus bodies, these authors sugdisease, the greater will be the differential diagnostic gested that one or both of the predisposing genes on uncertainty, and the more often will objective 11q encode tumour-suppressor proteins. Assuming confirmation be required. Of enormous importance that both genes code for functionally equivalent in genetic counselling is the ability to distinguish tumour suppressors, the Knudson hypothesis would between heritable and non-heritable types predict that all four alleles from the two genes have ( phenocopies) of a distinct clinical entity. In this to be turned off before glomus tumours can develop.
review, we concentrate upon disease prediction in In this respect, genomic imprinting would account hitherto asymptomatic individuals. for the silencing of the two maternal copies, whereas a paternally inherited mutation in one of the genes
Locus heterogeneity
would represent the third hit. A single somatic mutation in the remaining active paternal copy Gene mapping has already shown its importance to clinical medicine through the locus (non-allelic) would subsequently suffice to initiate tumour growth.
heterogeneity it has revealed.12 Locus heterogeneity is said to occur in cases where a similar disease X chromosome inactivation phenotype arises as a consequence of defects in different genes. Locus heterogeneity has extremely Since females have two X chromosomes whilst males have only one, some means of equalizing the expresimportant implications for disease diagnosis, prediction and treatment, since the nature of the clinical sion of X-linked genes between the sexes must be available. This is achieved by inactivating one X phenotype or the age of onset and severity may differ between non-allelic forms of the disorder(s). chromosome at random in every female cell. This inactivation is controlled by an X-linked gene which Thus mutations in at least seven different loci have been implicated in the causation of Charcot-Marieis only active on otherwise inactive X chromosomes. Occasionally, in the presence of an abnormality on Tooth disease (reviewed in Harding13). RFLP tracking (see below) has permitted the confirmation of one X chromosome, skewed X inactivation may occur, with preferential inactivation of the normal X locus heterogeneity in a variety of other conditions. Over 20 loci where mutations cause retinitis chromosome resulting in manifestation of disease pigmentosa have been mapped. There are at least
Multifactorial inheritance
eight autosomal loci and three X-chromosomal loci A large number of people living in societies with a responsible for causing non-syndromic retinitis pighigh individual life expectancy will sooner or later mentosa in different kindreds (reviewed in Wolf14).
suffer from an adult-onset disease in which genes Some of the genes involved in these disorders have related to the disease have probably played a major now been isolated and characterized. gene defects', must be regarded in some way as patients is usually predictable from the nature of the multifactorial. This truism should not, however, underlying mutational lesion although it may still obscure the fact that those genetic factors which occasionally vary between individuals bearing the influence the genotype-phenotype relationship in a given disorder can often be studied individually and same mutation. may even be quantified, thereby improving the gation. In principle, any two genetic loci on the accuracy of prognostic predictions. same chromosome should be transmitted together A number of different factors (of both genetic and from one generation to the next. This implies that environmental origin) can account for the fact that polymorphic loci in the vicinity of a mutated gene two individuals with identical genetic lesions at a can serve as markers for the presence of a given given locus can experience quite different clinical gene lesion. The pathway of the mutation through symptoms. These factors determine the relationship family pedigrees may thus be tracked by studying between genotype and phenotype.14 Among the the segregation of marker alleles instead of diseasegenetic modifying factors are the proportion of cells related alleles. However, in practice, homologous bearing the lesion (mosaicism), the activity state of chromosomes recombine and exchange pieces the chromosome carrying it (X-inactivation and of DNA during meiosis in a process termed crossingimprinting-see above), the effects of other loci and over. Thus with respect to any pair of loci on their protein products (epistasis), the status of the homologous chromosomes, germ cells may be other allele and the variable expression of the wilddivided into two groups: recombinants and nontype or mutant allele as a consequence either of recombinants. alternative mRNA processing or the influence of
The observed proportion of recombinants with genetic variation in the gene promoter region.
respect to any two loci is termed their recombination Genetic imprinting and X-inactivation are epifraction, (h). h equals exactly half the probability of genetic mechanisms for phenotype modification (see at least one cross-over event taking place and is above). They are temporal and/or tissue-specific therefore a function of the physical distance between phenomena and are (at least in principle) reversible, the two loci. The closer the loci are, the smaller the although the sequelae of an imprinted gene may recombination fraction, with a value of zero attained persist, particularly if it has shaped early morphogenwhen both loci coincide. The upper limit of h is 0.5, esis or organogenesis.
corresponding theoretically to the recombination Somatic mosaicism is an important cause of fraction between loci located on non-homologous phenotype modification resulting in variation in the chromosomes. Clearly, the study of recombination clinical expression of an inherited trait or disorder fractions represents a useful means to analyse and (reviewed in Hall22). The proportion of affected cells localize new disease loci. in the expressing tissue(s) of the individual concerned Major goals of linkage analyses are (i) to prove is a prime determinant of phenotypic severity.
that the marker and mutated gene are linked and (ii) Mosaicism for a specific gene mutation may be to estimate h. Evidence in favour of, or against, a confined to somatic cells or to the germline, or be given recombination fraction is expressed by the present in both, depending upon the developmental quantity z(h), termed the lod score.23 z(h) is a stage at which the lesion occurred. If the germline logarithmic value, and a positive value of argues in of that individual is affected, then subsequent profavour of linkage. If h is considerably smaller than geny will be at risk of inheriting a much more 0.5, then a lod score exceeding 3 (chance of greater severe phenotype. Germline mosaicism provides an than 1000:1) is usually regarded as sufficient evidexplanation for the inheritance pattern in cases where ence for linkage. If z(h) is less than -2 (chance of multiple affected offspring are born to clinically and less than 1:100), then recombination fractions smaller phenotypically normal parents. It arises through the than h are excluded from being the true value. h is occurrence of a de novo mutation in a germline cell estimated by that recombination fraction which yields or one of its precursors during the early embryonic the maximum lod score, i.e. the maximum likelihood. development of the parent. Although the frequency
The greater the number of informative families with which germline mosaicism occurs may well studied, the more reliable and convincing are the differ quite markedly between different disease states, results generated from linkage studies. The overall it does provide an important explanation for the lod score is calculated as the sum of the lod scores recurrence of rare mutations within a single family, obtained in separate families. and should always be considered when counselling
Once the linkage between a marker and a disease such cases.
gene has been established, and when the recombination fraction, h, between them is known with sufficient accuracy, then the marker can be employed in
Indirect disease diagnosis and the diagnostic testing. To determine whether an prediction individual carries one or more mutant alleles, and if phenotypic information regarding carriership is lack-
Linkage analysis
ing, chromosomes carrying the mutation(s) must be identified in other family members, preferably includGenes are organized in chromosomes and hence do not always obey Mendel's law of independent segreing the parents. If the marker allele characterizing a mutant chromosome is also present in the proband, protein [GNAS1 gene] in McCune-Albright syndrome). Different point mutations in the adult skeletal then this may indicate that they have also inherited the mutation. However, if marker and disease gene muscle sodium channel a subunit (SCN4A) gene cause hyperkalaemic periodic paralysis and do not coincide (i.e. if h>0), then the identification of mutants by marker alleles generates probabilistic paramyotonia congenita, by interfering with normal voltage-sensitive inactivation of the sodium current. results. The efficiency and accuracy of risk assessment can be improved in several ways, e.g. by the Dominant negative mutations, in which product from the mutant allele inactivates the wild-type use of flanking markers and the creation of haplotypes, phenotypic markers (e.g. serum creatine kinase product, usually occur in genes that are involved with protein subunit activity or assembly (e.g. some levels in Duchenne muscular dystrophy), and linkage disequilibrium data.
somatic TP53 gene lesions responsible for malignancy). Toxic precursors or waste products may While linkage analysis remains important for some diseases, increasingly, direct testing for diseaseresult from dominant mutations in a number of proteins including b-amyloid precursor protein (APP) causing mutations is taking its place. The major consequences of this change are a greatly improved and prion protein (PRNP). Mutations causing altered structural proteins may result in a more severe speed and reliability of diagnosis, and elimination of the need to involve other family members in predictphenotype than loss-of-function mutations (e.g. mutations of fibrillin (FBN1) in Marfan syndrome). Finally, ive gene testing. Nevertheless, linkage analysis remains useful for some diseases, even when the some dominant mutations may result in new protein functions that are deleterious (e.g. the c-ABL/BCR disease gene is known. 'Exclusion testing' using linkage analysis has sometimes used in conditions fusion products in the 9;22 Philadelphia translocation). such as Huntington's disease, enabling fetal risk to be refined (e.g. to determine whether a 25% risk Characterized gene mutations have been found within coding sequences, promoter regions, in splice can be adjusted towards 50% or 0%) without altering the parental 50% risk. Linkage analysis is still comjunctions, within introns and in polyadenylation sites (see below and Figure 1 ). Indeed, they may interfere monly used for families in cases where the disease gene has been isolated but mutation screening would with any stage in the pathway of expression from gene to protein product. Table 1 
Genes, mutations and disease
Mutations are then secondarily divided into four categories; promoter function, gene structure, RNA There are a variety of mechanisms by which mutations can give rise to an inherited disease. Mutations processing and translation. Some gene lesions may be placed into more than one category. For example, may lead to a loss or gain of gene function (reviewed in Wilkie1). In dominant disorders, haploinsufficimissense mutations with drastic effects on protein structure and stability, or which served to activate ency, or reduced gene function may result from inactivation of one of a pair of alleles. This may an exonic cryptic splice site, can fall into both categories. Similarly, a missense mutation close to cause disease through the reduced synthesis of tissuespecific proteins synthesized in large quantities (e.g.
an intron/exon splice junction could affect mRNA splicing efficiency as well as protein structure. The globins), by interference with a rate-limiting step of a metabolic pathway (e.g. low-density lipoprotein effects of specific amino acid substitutions on protein structure are the subject of several reviews.24-26 receptor), or by reduced activity of a regulatory gene working close to a threshold value (e.g. RDS/peripherin in retinitis pigmentosa). In recessive disorders,
Methods of detecting mutations
loss of function is an invariable outcome of the mutant homozygous state.
Predictive testing for adult-onset genetic disease will often involve ascertaining whether or not a particular Gain-of-function mutations responsible for dominantly inherited disorders may result from a variety of pathological gene lesion is present in a given relative of a patient already known to suffer from the disease molecular mechanisms, including increased gene dosage (e.g. the PMP22 gene duplication in Charcotin question. As we have seen above, even although the disease-related gene may be unknown, if a Marie-Tooth disease 1A), increased or constitutive protein activity (e.g. activating mutations in the G sa linked marker is available, linkage analyses can be attempted to track the disease gene through the routinely employed in mutation detection and screening are outlined below. family pedigree. Such studies are inherently probabilistic in nature, and their reliability is critically dependent on the mode of transmission and penetr-
Southern and Northern blotting
ance of the disease under study, the informativity of the marker, the distance between marker and disease With the discovery of restriction enzymes, sitespecific endonucleases that cleave large DNA fragloci, the pedigree structure and availability of family members. In the ideal situation, linkage studies will ments at defined sites, and the development of techniques to mass-produce these fragments (DNA be unnecessary; both the identity of the defective gene and the nature of the gene mutation will already cloning), the way was open to analyse the fine structure of human genes and to begin to characterize have been established, and the task simply reduces to testing family members directly for possession of the genetic lesions underlying inherited disease. The first technique to make this possible was Southern that lesion. In the majority of cases, however, whilst the identity of the defective gene may be known, blotting.27 Total genomic DNA is cleaved with a restriction enzyme and transferred from the agarose the nature of the pathological lesion within it is not. One of a number of mutation screening methods gel upon which it has been size-fractionated to a porous membrane which serves as a solid support. can then be used to detect the lesion to ensure that subsequent predictive tests will be fast, accurate and It may then be challenged with a gene radiolabelled probe to reveal the structure of the homologous reliable. Some of the approaches and strategies region of DNA in the genome of both patients and heteroduplexes as a result of mutation may also be detected by denaturing gradient gel electrophoresis controls. The above mutation-screening techniques provide of specific target sequences in genomic DNA by little or no positional information on the mutation repeated cycles of (i) heat denaturation of the detected. Confirmatory DNA sequencing is therefore double-stranded template, (ii) primer annealing and always required,33,36,44 but there are many alternat-(iii) extension of the annealed primers with a ives for use in screening large numbers of patients thermostable DNA polymerase. Target specificity is for mutations.45,46 Restriction enzyme cleavage or determined by the choice of short (~20 bp) oligonuallele-specific oligonucleotide discriminant hybridcleotide primers which are designed to hybridize to ization47 performed on PCR-amplified DNA samples opposite DNA strands flanking the sequence to be are two other options. In the future, mutation detecamplified, with their 3' ends facing inwards.
tion promises to become quicker, easier and cheaper. Successive cycles of amplification result in a continuIndeed, automation may include the production of ous doubling of, and exponential increase in, the miniature hand-held diagnostic devices48 which sequence copy number as newly synthesized copies could potentially be used in the doctor's surgery. become available for primer binding. This extremely versatile technique is typically capable of amplifying
The nature of human gene mutation a single copy of a DNA sequence from the human genome approximately 100-fold in a few hours. The
One goal of predictive testing in adult-onset disorders is to be able to infer the likely clinical phenotype theory and practice of PCR have been well reviewed elsewhere. [30] [31] [32] [33] (e.g. age of onset, severity) from knowledge of the nature of the underlying gene mutation. The nature of the genetic lesion involved will also determine PCR-based methods of mutation detection The interested reader is referred to Cooper and mentioned below. None detect all potentially detectKrawczak21 for in-depth coverage of this topic. These able lesions within a gene and they vary with respect different types of lesion will nevertheless be briefly to such matters as ease of use, equipment requirereviewed here. ments and safety considerations.
The chemical mismatch cleavage technique37 serves to detect mismatched bases in hybrid duplexes
Single base-pair substitutions within the formed between wild-type and mutant DNAs, and coding region was first applied diagnostically to the detection of single base-pair substitutions in the factor IX (F9) Roughly 25% of point mutations are CG TG or CG CA transitions, representing a 8-fold higher gene causing haemophilia B using genomic DNA from the patients concerned.38 Mismatches within frequency for this dinucleotide than that predicted from random expectation.21,49 This is thought to be scriptional initiation and serve to decrease (or less often, increase) the level of mRNA/protein product due to the hypermutability of the methylated dinucleotide CpG; spontaneous deamination of synthesized. What these lesions have in common is their ability to alter or abolish the binding capacity 5-methylcytosine (5mC) to thymidine in this doublet gives rise to C T or G A transitions depending of cis-acting DNA sequence motifs for the transacting protein factors that normally interact with upon the strand in which the 5mC is mutated. CpG hypermutability in inherited disease implies that the them. CpG sites in question are methylated in the germline and thereby rendered prone to 5mC deamination.
Gross gene deletions
The spectrum of point mutations not in CpG Gross gene deletions may arise through a number of dinucleotides is also non-random.21,49 In principle, different recombinational mechanisms including the non-randomness of the initial mutation event, homologous unequal recombination (occurring the non-randomness of the DNA sequences under between either related gene sequences or repetitive study, differences in the relative efficiency with elements). Alu sequences flanking deletion which certain mutations are repaired, differences in breakpoints have been noted in a considerable phenotypic effect (and hence selection), or a bias in number of human genetic conditions and may represthe clinical detection of such variants, may all play ent hotspots for gene deletions.21 a role in determining the observed mutational spectrum.
The majority of single base-pair substitutions caus-
Short gene deletions
ing human genetic disease alter the amino acid Deletion breakpoint junctions flanking short encoded (missense mutations), but a sizable propor-(<20 bp) human gene deletions are non-random tion result in the introduction of a termination codon both at the nucleotide and dinucleotide levels, an (nonsense mutations). The likelihood of clinical observation consistent with a sequence-directed detection is estimated to be about three times as mechanism of mutagenesis.21 Direct repeats flanking high for nonsense mutations as for missense mutathe deleted sequence are a common finding, consisttions. 21 Using a multi-domain molecular model of ent with a model of slipped mispairing at the the human factor IX protein, Wacey et al. 26 have replication fork. Two specific types of sequence have shown that the likelihood that a factor IX mutation been found at high frequency in the vicinity of short (causing haemophilia B) will come to clinical attengene deletions: polypyrimidine runs of at least 5 bp tion is a complex function of the sequence character-(YYYYY) and a 'deletion hotspot consensus sequence' istics of the factor IX (F9) gene, the nature of the (TGRRKM).21 amino acid substitution, its precise location and immediate environment within the protein molecule,
Short insertions
and its resulting effects on the structure and function of the protein.
That insertional mutagenesis might be as intrinsically non-random as point mutations and gene deletions was strongly suggested by the findings of Fearon
Single base-pair substitutions within splice et al.,51 who reported ten independent examples sites of DNA insertion within the same 170 bp intronic Splicing defects have been estimated to make up region of the DCC gene (a locus which has been between 8% and 15% of all single base-pair substituproposed to play an important role in human colorections causing human genetic disease.50 Mutations tal neoplasia; see below). Insertional mutations involappear to occur disproportionately at the most evoluving the introduction of <10 bp DNA sequence into tionarily conserved positions within the splice site.50 a gene coding region are (i) non-random and appear This illusion results from a detection bias, caused by to be highly dependent upon the local DNA the relative phenotypic severity of these lesions.
sequence context and (ii) may be explained by those Phenotypic consequences of splice site mutations mechanisms held to be responsible for gene include exon skipping and cryptic splice site utildeletions.21 ization.
Inversions Single base-pair substitutions within
Inversions are a highly unusual mutational mechanpromoter regions ism. The best known example is that found recently in the factor VIII (F8) gene causing haemophilia A: A number of mutations are now known which occur within gene promoter regions.21 These lesions disrupt this rearrangement occurs in about 40% of severely affected patients and recurs at high frequency.52,53 the normal processes of gene activation and tran-The mechanism responsible is thought to be homocerebellar ataxia type 1, fragile X E mental retardation, dentatorubral pallidoluysian atrophy, Machadologous intra-chromosomal recombination between a gene (F8A) located in intron 22 55 ). This mechanism was first reported as a cause of the fragile X syndrome, the most frequent disorders and their predictive type of inherited mental retardation, which is associimportance ated with the presence of a fragile site on the X chromosome (FRAXA). The brain-expressed FMR1
With the chromosomal localization, isolation and characterization of the underlying genes, predictive gene responsible was found to contain an ususual (CGG) n repeat which exhibited copy number varitesting for adult-onset disease is becoming increasingly possible. Molecular diagnostics may however ation of between 6 and 54 in normal healthy controls, between 52 and >200 in phenotypically normal be a double-edged sword, and new ethical questions concerning counselling before and after predictive transmitting individuals (the 'premutation') and between 300 and >1000 in affected males and testing, together with issues of confidentiality and possible stigmatization of those found to be predisfemales (the 'full mutation').56-59 Thus a continuum exists between a copy number polymorphism present posed to genetic disease, are having to be addressed. In principle, adult-onset disorders may arise as a in the general population, the asymptomatic premutation which involves limited expansion of (CGG) n result of the slow accumulation of a toxic substance, slow tissue death or through inability to repair DNA copy number, and the full mutation which appears to require copy number expansion beyond a certain damage. In practice, the reasons for late onset are usually unknown. With the new molecular genetic threshold value. It would appear that those alleles with a repeat copy number of <46 exhibit no techniques, however, an understanding of the molecular pathology of the disease is not required meiotic instability. The premutation represents a comparatively small increase in (CGG) n copy number for the development of a diagnostic or predictive test. In adult-onset disorders, it has often been difficult but is not associated with mental impairment (at least not in 97% of cases, a proportion comparable to distinguish low penetrance (see above) from the absence of a disease state in a given individual. to that in the general population). However, those individuals bearing the premutation exhibit a high Depending on the disease, the penetrance may approach 100% if the individuals carrying the disprobability of having either affected children or affected grandchildren. Expansion of premutations to ease-related allele live long enough. On the other hand, there may be individuals who carry the full mutations only occurs during female meiotic transmission. For alleles with 52-113 repeat copies, disease-related allele but who will never develop symptoms. Conventionally, this problem has been the premutation expands to the full mutation in 70% of transmissions whereas the corresponding figure approached by means of life tables (age-of-onset curves) which permit the empirical estimation of the for alleles with >90 repeat copies is 100%. The probability of repeat expansion thus correlates with probability that an at-risk yet asymptomatic individual will develop the disease in question (e.g. the repeat copy number in the premutation allele, consistent with a mechanism of slipped mispairing Huntington's disease62). The advent of genetic methods to allow predictive testing has provided an during replication. Expansion of a sequence can thus itself lead to further expansion, a process termed escape from the limitations inherent in the use of life tables, and has at least in principle made possible 'dynamic mutation' by Richards et al. 60 The discovery of this novel mutational mechanism an accurate assessment of individual risk based upon objective disease-specific criteria. From the patients' led to the recognition that the expansion of unstable repeats was responsible for other human inherited point of view, the decision to opt for predictive testing will depend very much upon their perceived diseases, often manifesting a wide range of clinical severity and exhibiting inheritance patterns which risk, the severity of the disease in question, the accuracy and reliability of predictive tests and the appear to be non-Mendelian. The other diseases are spinal and bulbar muscular atrophy, myotonic benefits accruing to them from early presymptomatic risk determination (e.g. prognostic information, prodystrophy, Huntington's disease (see below), spino-phylactic treatment). Clearly, the availability and Among those in whom misdiagnoses, sample mixup or clerical error have been excluded, it remains effectiveness of therapies will be major factors in the decision-making process.
unclear whether this is due to allelic or locus heterogeneity. The accuracy and reliability of new genetic tests will in turn be determined by many factors including
The association between unstable CAG repeat expansion and HD is only the beginning of the task locus heterogeneity, the nature of any underlying mutation or mutational mechanism, the type of test to unravel the molecular pathology of the defect and to design appropriate therapies. Thus expansion of (i.e. linkage analysis vs. direct gene analysis) and the influence of both environmental and epistatic factors.
the CAG repeat may well be influenced by other sequence variation at the HD locus78,79 or other loci. Various examples of common adult-onset disorders are now briefly reviewed in order to illustrate the What is the phenotypic effect of the CAG repeat expansion? Since HD is a dominant disorder, it importance of such factors as allelic heterogeneity, locus heterogeneity, variable penetrance, anticipaprobably results from a gain-of-function of the protein product, possibly associated with transglutaminationtion, epistasis and the genotype-phenotype relationship for accurate prediction of disease and effective mediated80 or glutamine zipper-mediated81 formation of intramolecular complexes. genetic counselling.
Predictive testing for HD had been available for some time prior to the cloning of the HD gene. Such
Huntington's disease
procedures involved the use of polymorphic markers flanking, and located at some distance from, the HD Huntington's disease (HD) is a neurodegenerative disorder, affecting about 1/10 000 people, which gene to track the disease allele through affected pedigrees.82,83 Since linkage analysis is indirect, the can be said to be inherited as a true autosomal dominant trait. This is because HD homozygotes are results were inherently probabilistic. In the absence of a therapy, many ethical issues concerning no more severely affected than heterozygotes. It is now known that, in the vast majority of cases, HD informed consent, the testing of children, exclusion testing during pregnancy and confidentiality have is caused by the expansion of an unstable CAG repeat (encoding a polyglutamine tract) within the been encountered.84 Now that direct mutation analysis of the HD gene is possible, diagnosis and HD gene which encodes the protein huntingtin.63 Normal individuals exhibit between 9 and 30 copies prediction of occurrence of HD will be that much more accurate. However, the test should still be of this repeat whereas HD patients almost invariably possess between 40 and 120 repeats.63-67 De novo interpreted with caution, because its specificity and sensitivity remain to be determined. expansion of a CAG repeat in sporadic HD is associated with the possession of an already large repeat of 34-38 units. 68 Thus an expansion of >40 Familial Alzheimer's disease repeats is strongly diagnostic of HD, 30-40 repeats are difficult to interpret and <30 repeats makes HD Alzheimer's disease (AD), an aetiologically heterogeneous disorder, is the most common cause of unlikely but does not exclude it. 69 HD exhibits anticipation in that a progressively dementia. It occurs with an incidence of 0.0035 between the age of 65 and 69 and 0.073 between earlier age of onset is often apparent in succeeding generations. The basis for this appears to be a the age of 85 and 89.85 Three different loci of major effect have so far been identified as being involved correlation between the length of the CAG repeat and the age of onset. The possession of longer in the aetiology of familial Alzheimer's disease (FAD; reviewed in Schellenberg.86 In the vast majority repeats (>55) is associated with an earlier age of onset.70,71 However, below 50 repeats, there is little (70%) of cases of early-onset FAD (<50 years of age), the disease is caused by mutations in a gene or no relationship with age of onset. Also, with a late age of onset, the effect of repeat length appears (AD3) on the long arm of chromosome 14.87-90 This gene encodes a protein (S182) with multiple transto diminish.72 Thus repeat number has little predictive value for individuals.69 Repeat expansion appears to membrane domains but it is still unclear how perturbation of this protein results in the pathogenesis be greater upon paternal transmission63,73-75 providing an explanation for the observed preponderance of AD. A second Alzheimer's susceptibility gene has been of affected fathers of patients with early-onset HD.
HD patients exhibit significant levels of somatic identified on the long arm of chromosome 191 and a number of different pathological lesions have been instability, resulting in repeat length mosaicism.76 This mosaicism appears to occur in a tissue-specific identified.92,93 This gene encodes a protein (STM2) which is highly homologous to the chromosomefashion; the cerebellum possesses smaller alleles than other regions of the brain.76 On rare occasions, HD 14-encoded S182, raising the possibility that both may play a role in the same biochemical pathway. patients do not exhibit CAG repeat expansion.77
At least seven different point mutations in the Venous thrombosis amyloid precursor protein (APP) gene on the long A hereditary predisposition to venous thrombosis arm of chromosome 21 have also been characterized may arise as a consequence of a lesion in any one in AD patients. A fragment of this protein, b-amyloid, of at least eleven different genes encoding is an important constituent of the senile plaques antithrombin III (AT3), factor V (F5), factor XII (F12), which characterize AD. These lesions are located three chains of fibrinogen (FBA, FBB, FBG), heparin within, or flank, the b-amyloid-encoding portion of cofactor II (HCF2), plasminogen (PLG), protein C the protein and appear to alter the cleavage of the (PROC), protein S (PROS) and thrombomodulin amyloid precursor protein and the secretion of the (THBD).111 Some 300 different gene lesions (single b-amyloid peptide.94,95 Mutations at this locus are base-pair substitutions, deletions and insertions) have associated with the development of late-onset FAD so far been reported at these loci in patients with (age 50-60) but only account for about 2-3% of thrombotic disease. cases of early-onset FAD. 96, 97 However, an inherited deficiency state does not In addition to these major gene effects, a fourth automatically imply that the individual concerned locus, the apolipoprotein E (APOE) gene on will come to clinical attention. Although homozychromosome 19q,98,99 is known to be involved in gous or compound heterozygous individuals will conferring susceptibility to late onset FAD (>60 almost certainly experience some thrombotic sympyears). Specifically, there is an association between toms (from relatively mild to neonatally fatal), most the APOE e-4 allele (Cys112 Arg) and late-onset heterozygotes probably go undetected. Thus clinic-AD100-104 the frequency of the e-4 allele is around ally symptomatic AT3 deficiency in the general 0.40 in AD patients, compared to about 0.16 in population occurs at an 80-fold lower frequency Caucasian controls.105 Further, the risk of AD (f=2.1×10-5) than does the clinically asymptoincreases and the mean age of onset decreases in matic deficiency state (f=1.65× 10-3). 112 Similarly, proportion to the number of APOE e-4 alleles.99 This clinically symptomatic protein C (PROC) deficiency translates into an odds ratio of about 6 for those occurs at a 23-52-fold lower frequency (f= carrying one or more e-4 alleles. There are however 2.8-6.2×10-5) than its asymptomatic counterpart two problems with the direct use of these association (f=1.4×10-3).113-115 One gene lesion (factor V data for predictive purposes. First, since some 40% Leiden, Arg506 Gln), implicated in the aetiology of AD patients do not possess the e-4 allele, its of perhaps 30% of all cases of familial thrombotic presence is neither a necessary nor a sufficient disease, occurs with a prevalence of between 2% condition for disease pathogenesis. It may be that and 7% in the general population,116-118 but only a the e-4 variant does not so much increase the risk small fraction of carriers are clinically affected. of AD as lower the age of onset and possibly Thus, a defect in any one of the above mentioned accelerate disease progression in those already pregenes is on its own probably insufficient to cause disposed. Secondly, for it to have any predictive thrombosis. value at all, it will be necessary to perform epidemiolOther predisposing factors such as pregnancy, ogical studies of APOE allele frequencies in patients surgery, trauma and contraceptive pill usage appear and controls from different populations and ethnic to be required to precipitate a thrombotic episgroups. Finally, APOE interacts with both b-amyloid ode.119,120 Genetic factors are clearly also involved. and microtubule-associated proteins.106 Whilst the For example, genotypic variation in the PROC gene APOE e-4 variant is thought to promote the deposipromoter influences transcriptional efficiency of the tion of b-amyloid in senile plaques and cerebral PROC gene, the plasma protein C concentration and vessels,107 the precise mechanism by which the e-4 ultimately thrombotic risk.121,122 Epistatic effects may variant contributes to the pathogenesis of AD remains also play a role. Thus in the Dutch population, elusive. To make predictive testing even more difficoinheritance of the factor V Leiden mutation with cult, it may be that the influence of the APOE protein C deficiency has been shown to increase the modifier locus is itself modified by specific alleles at risk of an individual coming to clinical attention by unlinked loci e.g. a1-antichymotrypsin (ACT )108 and some six-fold,123,124 although this risk may vary very-low-density lipoprotein receptor (VLDLR). 109 between different populations.125 Similarly, coinheritThere are still several families who do not exhibit ance of the factor V Leiden mutation with protein S mutations in the known AD susceptibility genes,92,93 deficiency126 and antithrombin III deficiency127 also suggesting that even more AD loci remain to be increases the risk of an individual coming to clinical discovered. The combination of variable penetrance attention. The latter study has provided a potential and locus heterogeneity exhibited by FAD has made explanation for the particularly severe form of AT3 genetic risk analysis difficult, and the genetic deficiency segregating in some families. This is because the AT3 (chromosome 1q23-q25.1) and the counselling of at-risk individuals hazardous.110 F5 (1q21-q25) genes are both present in the same is considerable intrafamilial variability with respect to clinical severity and age of onset,141 the identificaregion of the long arm of chromosome 1 and therefore have the potential to cosegregate through tion of the particular gene involved in a given family will be of some prognostic value, and accurate family pedigrees. Such combinatorial effects of different loci will not be rare, since many of the deficiency predictive testing for PKD may aid early clinical management of those proven to have a mutation. states giving rise to thrombosis are individually fairly frequent in the general population (e.g. AT3, 0.0016; PROC, 0.0014; F5, 0.02-0.07; F12, 0.023; HCF2, Familial hypercholesterolaemia 0.009).
ATIII deficiency and protein C deficiency are Individuals with familial hypercholesterolaemia (FHC) manifest defective catabolism of low-density unusual in that they are recessive disorders with respect to both mortality and reproductive fitness, lipoprotein (LDL), resulting in a 2-3-fold increase in circulating plasma LDL cholesterol, and excessive but dominant disorders with respect to morbidity, albeit with reduced penetrance.119,128,129 Prophylactic deposition of cholesterol in the arterial wall, leading to premature atherosclerosis and coronary heart anticoagulation is an effective treatment for those who have already exhibited thrombotic manifestadisease. Heterozygous FHC is one of the most common single-gene disorders, and affects about 1 tions. However, it is not normally recommended for relatives of the clinically affected individual, even if in 500 individuals. The much rarer homozygotes are more severely affected and exhibit a much earlier they are proven carriers of a predisposing gene lesion, unless there are clear mitigating circumstances onset of disease; in these individuals, angina pectoris, myocardial infarction and sudden death usually e.g. trauma, surgery. This is because, as indicated earlier, the penetrance of predisposing gene lesions manifest between the ages of 5 and 30. Predictive identification of those most at risk is important, since is usually low and many other factors contribute to the eventual likelihood of a thrombotic episode.
prophylactic treatment with cholesterol-lowering agents can help to reduce mortality and morbidity.142 Detection of clinically asymptomatic heterozygous individuals by molecular genetic means may thereMutations in the low-density lipoprotein receptor (LDLR) gene are a major cause of familial hypercholefore be of limited predictive utility. sterolaemia, and over 100 different point mutations and short deletions have been characterized to date.
Autosomal dominant polycystic kidney
Extensive variation in clinical severity has been noted disease in FHC and this may be attributed, at least in part, to allelic heterogeneity.143,144 Perhaps the best Autosomal dominant polycystic kidney disease (PKD), usually a late-onset disorder, affects about 1 example of the effect of allelic heterogeneity is the comparison of patients homozygous for two distinct in 1000 individuals. It causes hypertension, urinary tract infection, nephrolithiasis and ultimately renal LDLR gene lesions.145 individuals with >10 kb deletion of the LDLR gene exhibited higher mean plasma failure, as well as extra-renal manifestations in the cardiovascular system (e.g. cerebral arterial aneurcholesterol levels, an earlier age of onset of coronary heart disease and a higher frequency of coronary ysms and heart valve prolapse) and gastrointestinal tract (e.g. hepatic cysts and bowel diverticudeaths than individuals with a Trp66 Gly missense mutation. Although allelic heterogeneity is very losis).130 PKD is now known to exhibit considerable locus heterogeneity, which greatly complicates important, intra-familial variability in clinical phenotype among carriers of the same lesion also occurs.146 genetic counselling in affected families. The majority of cases of autosomal dominant PKD have been One explanation for intra-familial variability in clinical phenotype may be the cholesterol-lowering ascribed to mutations in the PKD1 gene now identified on the short arm of chromosome 16.131 The effect of the E2 isoform of apolipoprotein E (APOE) encoded by the e2 allele.147 APOE plays an important mean age of onset of end-stage renal disease in PKD1 patients is about 56 years whereas it is about 70 in role in the regulation of plasma LDL-cholesterol levels. The E2 isoform of APOE binds poorly to non-PKD1 families.133 A second gene locus, PKD2, is present on chromosome 4134,135 and the PKD2 LDLR, and it is thought that in its presence, inefficient delivery of cholesterol to hepatocytes may gene has recently been cloned.136 There is also evidence for a third gene (PKD3) unlinked to the up-regulate the LDLR. The LDLR gene is not the only locus known to other two. 137, 138 A European study has estimated the prevalence be defective in hypercholesterolaemia. Thus between 2% and 5% of FHC patients possess a substitution of PKD1 among patients with ADPKD to be 85%.139 However, it is now known that PKD2 has a less of Arg3500 by Gln in the putative LDLR-binding domain of apolipoprotein B-100, the main componsevere phenotype,140 making it possible that PKD2 families have been under-ascertained. Although there ent of LDL.148,149 This APOB gene mutation reduces the affinity of LDL for LDLR, although it results in a usually of the order of 45-50%.152 One function of the encoded protein, p53, is to act as a recessive less severe hypercholesterolaemia than found in FHC. Even in the absence of an LDLR defect, the clinical tumour suppressor which, when inactivated, no longer exerts its protective influence through a DNA severity associated with the heterozygous possession of the Arg3500Gln APOB gene mutation varies damage/cell cycle control pathway. Interestingly, some TP53 mutations can also activate p53 as an enormously from person to person.150 A second, much rarer, APOB gene lesion, which substitutes oncogene. Cancer, however, is clearly a multi-step process with many more genes involved in the Cys for Arg3531 in the same region, also decreases LDLR binding affinity and results progression toward malignancy. The complexity of this process is illustrated briefly by describing our in FHC. 151 current understanding of two common cancers, those of the colon and breast:
Familial cancers
Cancer may arise as a result of chromosome loss,
Colon cancer
chromosome rearrangement or via more subtle mutations in one or more of a large number of genes. Colorectal cancer is the most common cause of early death in non-smokers in the Western world. Familial Cancer is a multi-step process and most cancers arise as a consequence of somatic mutations which colon cancer falls into two main categories, familial adenomatous polyposis (FAP) and hereditary nonby definition are not inherited. Whereas inherited mutations may predispose to cancer, somatic mutapolyposis colon cancer (HNPCC) (reviewed in Burt et al. 153) . FAP is an autosomal dominant condition tions serve to determine the site of the tumour. Cellular genes in which mutations can give rise to characterized by polyps (adenomas) which, although not initially malignant, may evolve into an invasive tumours are basically of three types. (i) Protooncogenes. The products of these genes normally carcinoma. A large number of mutations, both germline and somatic, have now been reported in the promote cell proliferation, and the dominantly-acting mutant products are excessively or inappropriately underlying APC tumour suppressor gene.154 HNPCC is also inherited in an autosomal dominant fashion active (i.e. they exhibit a 'gain-of-function'). Activation of a proto-oncogene may occur by single and results from mutations in at least four mismatch repair genes: MLH1 (chromosome 3p), MSH2 (2p), base-pair substitution (e.g. RAS causing a variety of tumours), gene amplification (e.g. N-MYC in PMS1 (2q) and PMS2 (7q). These lesions cause a genome-wide instability of microsatellite DNA neuroblastoma) or translocation (e.g. the fusion of the chromosome 9 ABL oncogene to the sequences, thereby resulting in a gain of alleles for a high proportion of markers tested, regardless of chromosome-22-encoded BCR gene in chronic myeloid leukaemia). (ii) Tumour suppressor genes ('antitheir chromosomal location (reviewed in Dunlop155). The development of colon cancer can be envisaged oncogenes'). These are genes whose wild-type products inhibit cell proliferation and whose mutant as the steady accumulation of non-allelic mutations each of which confers a growth advantage upon the products have lost their function. Since both alleles must be inactivated to alter cell function, tumorigencell. Since inherited mutation of the APC gene is sufficient for polyposis to occur, loss of the second esis requires a 'two-hit' mechanism. Usually, the first mutation is inherited whilst the second involves the APC allele may be an early event in colon cancer. Some adenomas have K-RAS (12p) oncogene mutaloss of all or a part of a specific chromosome by deletion, non-disjunction, mitotic recombination etc tions which may speed the hitherto benign growths along the path to malignancy. Additional inactivating leading to a constitutional loss of heterozygosity for genetic markers in the region of the gene in tumor mutations in the DCC (18q) and the TP53 (17p) tumour suppressor genes probably lead to a further tissue (e.g. at 5q21-22 near the APC gene in colon cancer, see below). (iii) DNA repair genes. The loss of growth control. Since 15-20% of colon tumours have mutations in mismatch repair genes, it products of these genes are involved in maintaining the integrity of the genome and the fidelity of may be that lesions in these 'mutator genes' dramatically increase the probability of mutation in the Kinformation transfer. Several mismatch repair genes are known whose protein products are involved in RAS, DCC and TP53 genes, thereby greatly speeding up progression toward malignancy. An understanding checking the DNA for mismatched base-pairs. The loss of both alleles leads to inefficient DNA replicaof the molecular genetics of this condition should potentiate the early identification of at-risk indition and repair.
The quest for the 'Rosetta stone' of cancer briefly viduals, allow the stage-specific assessment of tumour progression in affected individuals and aid the stopped at the door of TP53, the most widely mutated gene in human tumorigenesis; the frequency of development of new therapeutic approaches to colorectal cancer. mutation varies from one cancer to another, but is role in the aetiology of schizophrenia: a concordance Breast cancer of 45% for identical twins as compared to 15% for Only a small proportion (5-10%) of cases of breast fraternal twins.166 cancer is attributable to inherited factors, but this Early genetic linkage studies suggested a locus of proportion is higher in families with onset before the major effect on chromosome 5, but this has not been age of 45. It nevertheless manifests an autosomal substantiated.167 Linkage has been repeatedly dominant pattern of inheritance with high penetrance reported for some families using markers on chromo-(i.e. a lifetime risk of tumour development close to some 6p22-p24,168-171 whilst other reports suggest 100%). The major locus responsible (BRCA1) has the possible existence of susceptibility loci on chrobeen localized to chromosome 17q21, and inherited mosomes 3p and 8p.172 Such results should be lesions are thought to be responsible for development treated with caution until confirmatory evidence is of breast cancer in 80-90% of families with both forthcoming. This is because of (i) the inherent breast and ovarian cancer but only about 40-50% problems of disease diagnosis and ascertainment in of families with breast cancer alone (reviewed in this condition, (ii) the relatively low lod scores Bishop156). Interestingly, some 86% of lesions generated so far, bearing in mind the number of detected are predicted to result in the production of markers tested, (iii) the difficulty in defining the a truncated protein. 157 Further, mutations occurring model of inheritance for linkage studies (not a in the 3' third of the gene appear to be associated problem when non-parametric methods such as with a lower proportion of ovarian cancer.158 One affected sib-pair analysis are used) and (iv) the fact caveat to bear in mind when attempting to assess that many studies have not scanned the entire the significance of mutations found is that some genome before linkage data are reported. coding region variants are found in control populaMore promising has been the recent finding of tions of women.159 microdeletions of chromosome 22q11 in schizoInherited mutations in a second breast cancer phrenic patients with signs of velo-cardio-facial synsusceptibility locus, BRCA2, localized to chromodrome.173,174 These deletions have helped to define some 13q12, appear to account for an additional a 2 Mb region of the chromosome which may 40-50% of cases of familial breast cancer, but a harbour a schizophrenia susceptibility gene. The much lower proportion of cases with breast and shortest region of overlap between the deletions ovarian cancer.160-162 BRCA2 lesions are almost is 300 kb and includes the catechol-O-methyltransexlusively microdeletions which, as in the case of ferase (COMT ) gene. 174 The mechanism by which BRCA1, are predicted to result in the production of 22q11 microdeletions increase the risk of schizophrea truncated protein.
nia is unknown. It is also unclear why only a The genetics of breast cancer are as yet poorly proportion of the known 22q11 microdeletions are understood but there is already evidence for the associated with schizophrenia/psychosis. Linkage involvement of additional loci (H-RAS,163 TP53 and studies (e.g. Vallada et al.175 ) are necessary to confirm the ataxia telangiectasia gene, ATM) in hereditary these initial findings. The observation of Morris susceptibility to breast cancer. Such changes may be et al.176 that the genomes of schizophrenic subjects important prognostically; thus the presence of a TP53 exhibit a significantly higher frequency of CAG triplet mutation is associated with lower patient survival.
repeat expansion at undefined loci remains to be satisfactorily explained. The study of bipolar affective disorder (manicSchizophrenia and bipolar affective depressive illness) has followed a similar path. Early 182 Future studies promise to determine the genetic basis for of inheritance, incomplete penetrance, and difficulty in establishing reliable diagnostic criteria. This notthe twin clinical observations that mothers transmit bipolar affective disorder more often than fathers183 withstanding, schizophrenia has been known for some time to run in families: the risk for offspring of and that offspring of affected parents tend to experience a more severe illness with earlier onset.184 schizophrenic parents is 13%, considerably higher than that in the general population of approximately While possible explanations such as imprinting and anticipation spring to mind, it will be some consider-1% (reviewed in Plomin et al.166) . Adoption studies support the view that genetic factors play a major able time before gene cloning and characterization of specific gene lesions. Acceptance of new predict-
